Compare Ishares Msci Brazil ETF (EWZ) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs Novo Nordisk A/S — how do they compare? Ishares Msci Brazil ETF trades at $43.37 (market cap $11.30B), while Novo Nordisk A/S trades at $38.48 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 14.6× Ishares Msci Brazil ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Ishares Msci Brazil ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and Novo Nordisk A/S for 116 Days on average.
| EWZ | NVO | |
|---|---|---|
Market Cap | $11.30B | $165.31B |
Volume | 44,036,597 | 11,432,838 |
Sector | Broad Market / Factor | Health |
52-Week High | $43.00 | $63.98 |
52-Week Low | $28.79 | $35.29 |
Typical Hold Time | 50 Days | 116 Days |
Enterprise Value | — | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, is trading at $43.465, up 2.58% with a bullish technical signal from moving averages but bearish oscillators. The ETF shows strong institutional interest with unusual options activity and new positions from firms like Empowered Funds. Recent news highlights Brazil's upcoming election as a key market driver, with investors positioning for potential policy shifts under different candidates.
The outlook for EWZ hinges on Brazil's political landscape and commodity trends. Investment opportunities include geographic diversification and exposure to Brazilian stimulus policies, while risks involve election volatility and US-Brazil trade tensions. Wall Street shows cautious optimism with significant institutional accumulation despite competitive pressure from lower-fee alternatives like FLBR.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
